Acadia Pharmaceuticals
ACAD
219 hedge funds and large institutions have $4.11B invested in Acadia Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 82 increasing their positions, 69 reducing their positions, and 34 closing their positions.
51% more capital inflows, than outflows
Capital inflows: $519M | Capital outflows: $343M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 69
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
1.59% less ownership
Funds ownership: 100.05% → 98.47% (-1.6%)
3% less funds holding
Funds holding: 225 → 219 (-6)
24% less call options, than puts
Call options by funds: $52M | Put options by funds: $68.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$188M |
| 2 |
OrbiMed
New York
|
+$41.3M |
| 3 |
Elliott Management
New York
|
+$27.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.9M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$66.6M |
| 2 |
Jennison Associates
New York
|
-$39.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.7M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$33.5M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$20M |
ACAD Hedge Fund Activity: Q1 2017 in Review
219 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2017, worth a combined $4.11B — up 18% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ACAD positions and 34 closed out — a net gain of 3 holders — while 82 added to existing stakes and 69 trimmed.
The largest buyer was BlackRock, adding an estimated $188M. The largest seller was Millennium Management, cutting an estimated $66.6M.
- 219 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2017, down from 225 in Q4 2016.
- Funds reported $4.11B of Acadia Pharmaceuticals stock for Q1 2017, up 18% quarter-over-quarter.
- 37 funds opened new Acadia Pharmaceuticals positions in Q1 2017 and 34 closed out, a net change of +3 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $188M added.
- The largest Acadia Pharmaceuticals seller in Q1 2017 was Millennium Management, an estimated $66.6M sold.
Based on aggregated 13F filings for Q1 2017.